While there are limited preclinical GBM data on TIM-3 blockade, Kim’s group demonstrated a novel triple glioma therapy that combined dual TIM-3 and PD-1 blockade with stereotactic radiosurgery, showing a significant improvement in OS [112]. This evidence concerns the gene PDCD1 and glioma.